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  Prostatic acid phosphatase （PAP） concentrations were measured by radioimmunoassay （RIA）
kit（DR工・一917）．
  1） Flihe cgefficients of variance of PAP concentrations in inter－assay and intra－assay were 9．81±
4．450／． and 7．89±2．450／．．
  2） The recovery rates in dilution test and recovery test were 98．75士7．93％and 97，05±7。43％．
  3） Significant correlation （r＝＝O．687， p〈O．Ol） was seen between enzymatic assay （Bessey－Lowry
method） and RIA （PA？ concentrations＞2．O ng／ml）．
  4） There was no sex difference of PAP concentrations in nor皿al adults， such as O．417士0．411ng／
ml（n＝・52）in normal males and O．435土α577 ng／ml（n＝10）i11．nor皿al females， and the correlation
between PAP concentration and aging was not significant．
  5） AII of the untreated ’patients and 65．50／． of the treated patients with prostatic cancer of stage
D had higher PAP concentrations than 2．’O ngfml in sera， and RIA of PAP seemed to be more specific
to’垂窒盾唐狽≠狽奄?．pancer than enzymatic assay in which 91．60／． and 23．30／o of those had increased
activities． But PAP concentrations were elevated falsely in 2 oUt of 11 patients with benign prostatic
hyperplasia．




























Table 1． Subjects of examinations．
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（ ）： No． of hormone therupy
※綱㎝α4，rnetastutic b㎝∋tumer 2，（繭l cα．1，㎏。ロ．1、，
lung c。n。er 2，9蹴たacmoer 1， ureterctl tuT・。r 1， bk）Clder tLrrTxx 1．
Table 2． Standard curve．

















































































































  各標準溶液または検体の平均計数率（B）                     × 100
Table 4． Dilution test．
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Correlation between PAP concentration and L－tartrate labile ACP．


















  Table 5． PAP concentration in blood and
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Fig．3． PAP concentration and agc of normal
    males．                    NS＝not sigificant
         Table 6． PAP concentrations in prostatic cancer and other diseases．
o
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’森下・ほか：DRL－917キヅト・PSAP 903
Table 7． Frequency of increased PAP concentration or activity．
Na Pts．
No． ％ of increcised PAP
RIA test Enzym口曹ic fe5奮
Prvstatic cancer
stoge B















































50歳， 16t ti）， 0，553±0．309 （51～60歳， 10｛列）， O．415
＝ヒ0．212 （61～70歳， 10｛ 旺）， 0．270±0．363 （71～SO．k，
5例）と各年齢層．間に有意の差はなかった．
 2）血清と骨髄血のPAP
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Durat ion of therapy
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PAP concentration and hormone therapy
m prostatic cancer．
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